Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
Brickell Biotech, Inc. ( NASDAQ:BBI ) shareholders will doubtless be very grateful to see the share price up 75% in the...
Topline results from the U.S. pivotal Phase 3 program anticipated in the fourth quarter of 2021 Sofpironium bromide gel, 5% (ECCLOCK®) recently launched in Japan by development partner, Kaken PharmaceuticalBOULDER, Colo., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced dosing ...
Kaken plans to launch ECCLOCK® for the treatment of primary axillary hyperhidrosis in Japan on November 26, 2020 \- - - ECCLOCK® placed on Japan’s National Health Insurance (NHI) drug reimbursement price listBOULDER, Colo., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that i...
BOULDER, Colo., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that its management team will participate in the Piper Sandler 32nd Annual Healthcare Conference taking place December 1-3, 2020. Brickell’s Chief Executive Officer, Robert Brown, will present a corporate overview a...
Recently completed capital raise expected to fully fund U.S. pivotal Phase 3 program, with topline results anticipated in Q4 2021 \- - - Initiated the Cardigan I study, the first of two U.S. pivotal Phase 3 clinical studies evaluating sofpironium bromide gel, 15% as a potential treatment for primary axillary hyperhidrosis \- - - On track to initiate the Cardigan II study, the second U.S. pivotal Phase 3 clinical study, later this year \- - - Planned commercial launch of ECCLOCK® in Japan b...
NEW YORK, NY / ACCESSWIRE / November 12, 2020 / Brickell Biotech Inc (BBI) (NASDAQ:BBI) will be discussing their earnings results in their call to be held on November 12, 2020 at 4:30 PM Eastern Time.